Anti-metastatic activity, chemotherapeutic enhancement and therapeutic potential of targeting Hsp90 with ganetespib in triple negative breast cancer

被引：0
|
作者：
Proia, D. A. [1 ]
Zhang, C. [1 ]
Sequeira, M. [1 ]
Jimenez, J-P [1 ]
He, S. [1 ]
Nagai, M. [1 ]
Acquaviva, J. L. [1 ]
Smith, D. L. [1 ]
Sang, J. [1 ]
El-Hariry, I. [1 ]
机构：
[1] Synta Pharmaceut, Lexington, MA USA
来源：
CANCER RESEARCH | 2013年 / 73卷
关键词：
D O I：
10.1158/0008-5472.SABCS13-PD5-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD5-3
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
    Mumin, Nuramalina H.
    Drobnitzky, Neele
    Patel, Agata
    Lourenco, Luiza Madia
    Cahill, Fiona F.
    Jiang, Yanyan
    Kong, Anthony
    Ryan, Anderson J.
    BMC CANCER, 2019, 19 (1)
  • [22] Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
    Nuramalina H. Mumin
    Neele Drobnitzky
    Agata Patel
    Luiza Madia Lourenco
    Fiona F. Cahill
    Yanyan Jiang
    Anthony Kong
    Anderson J. Ryan
    BMC Cancer, 19
  • [23] Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
    Julie C. Friedland
    Donald L. Smith
    Jim Sang
    Jaime Acquaviva
    Suqin He
    Chaohua Zhang
    David A. Proia
    Investigational New Drugs, 2014, 32 : 14 - 24
  • [24] Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
    Friedland, Julie C.
    Smith, Donald L.
    Sang, Jim
    Acquaviva, Jaime
    He, Suqin
    Zhang, Chaohua
    Proia, David A.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (01) : 14 - 24
  • [25] Geraniol and Citral as potential therapeutic agents targeting the HSP90 activity: An in silico and experimental approach
    Gaonkar, Roopa
    Singh, Jitender
    Chauhan, Arushi
    Avti, Pramod K.
    Hegde, Gurumurthy
    PHYTOCHEMISTRY, 2022, 195
  • [26] Targeting HSP90 in breast cancer: ENCHANT-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic HER2 positive or triple negative breast cancer (TNBC)
    Cameron, D.
    Spector, N.
    Gomez, H.
    Hickish, T.
    Vandat, L.
    Kim, S. B.
    Sheldon, E.
    El-Hariry, I.
    Perez, E.
    Awada, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S98 - S98
  • [27] Targeting HSP90 in Gynecologic Cancer: Molecular Mechanisms and Therapeutic Approaches
    Min, Lu
    Li, Xuewei
    Liang, Lily
    Ruan, Zheng
    Yu, Shaohui
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2025, 83 (01) : 177 - 192
  • [28] Anti-metastatic platinum through glycan targeting in breast cancer
    Katner, Samantha J.
    Peterson, Erica J. Peterson
    Katsuta, Eriko
    DeMasi, Stephanie C.
    Koblinski, Jennifer
    Takabe, Kazuaki
    Farrell, Nicholas P.
    CANCER RESEARCH, 2017, 77
  • [29] MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer
    Wang, Wanqin
    Zhao, Jun
    Wen, Xiaoxia
    Lin, Curtis Chun-Jen
    Li, Junjie
    Huang, Qian
    Yu, Yongqiang
    Lin, Shiaw-Yih
    Li, Chun
    CONTRAST MEDIA & MOLECULAR IMAGING, 2017,
  • [30] Anti-metastatic and anti-proliferative activity of eugenol against triple negative and HER2 positive breast cancer cells
    Abdullah, Mashan L.
    Hafez, Mohamed M.
    Al-Hoshani, Ali
    Al-Shabanah, Othman
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2018, 18
12345